Indexed keywords
CABOZANTINIB;
CRIZOTINIB;
DABRAFENIB;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
MITOGEN ACTIVATED PROTEIN KINASE;
MONOCLONAL ANTIBODY;
PROTEIN RET;
PROTEIN ROS1;
PROTEIN TYROSINE KINASE;
RAF PROTEIN;
REGORAFENIB;
TRAMETINIB;
UNCLASSIFIED DRUG;
VASCULOTROPIN RECEPTOR;
BREAST TUMOR;
CANCER IMMUNOTHERAPY;
COLORECTAL CANCER;
EDITORIAL;
GASTROINTESTINAL STROMAL TUMOR;
HEALTH CARE CONCEPTS;
HUMAN;
IMMUNOSTIMULATION;
LIVER CELL CARCINOMA;
LUNG NON SMALL CELL CANCER;
METASTATIC MELANOMA;
MOLECULARLY TARGETED THERAPY;
ONCOLOGY;
PERSONALIZED MEDICINE;
PRECISION MEDICINE;
PRIORITY JOURNAL;
PROSTATE TUMOR;
REGULATORY T LYMPHOCYTE;
SIGNAL TRANSDUCTION;
ADENOCARCINOMA;
ANILIDES;
ANTINEOPLASTIC AGENTS;
HUMANS;
INDIVIDUALIZED MEDICINE;
LUNG NEOPLASMS;
MEDICAL ONCOLOGY;
MOLECULAR TARGETED THERAPY;
PROTEIN-TYROSINE KINASES;
PROTO-ONCOGENE PROTEINS;
PYRAZOLES;
PYRIDINES;
1
84874466668
Other signalization
in press
Girard N (2012) Other signalization. Target Oncol (in press)
(2012)
Target Oncol
Girard, N.1
2
84872277710
Targeting ALK: A promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma
22968692 10.1007/s11523-012-0227-8
La Madrid AM, Campbell N, Smith S, Cohn SL, Salgia R (2012) Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol 7(3):199-210
(2012)
Target Oncol , vol.7
, Issue.3
, pp. 199-210
La Madrid, A.M.1
Campbell, N.2
Smith, S.3
Cohn, S.L.4
Salgia, R.5
3
84874496726
ALK inhibitors: A new targeted therapy in the treatment of NSCLC
in press
Gridelli C (2012) ALK inhibitors: a new targeted therapy in the treatment of NSCLC. Target Oncol (in press)
(2012)
Target Oncol
Gridelli, C.1
4
84866609972
Randomized phase III trial of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib(SU): GRID trial. Proceedings of ASCO LBA 10008
Demetri GD, Reichardt P, Kang Y et al (2012) Randomized phase III trial of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib(SU): GRID trial. Proceedings of ASCO LBA 10008. J Clin Oncol 30
(2012)
J Clin Oncol , pp. 30
Demetri, G.D.1
Reichardt, P.2
Kang, Y.3
5
83255186301
Multi-targeted tyrosine kinase inhibitors in clinical development: Focus onXL-184 (cabozantinib)
DW B, ER K, Jmeno A (2011) Multi-targeted tyrosine kinase inhibitors in clinical development: focus onXL-184 (cabozantinib). Drugs Today 47(11):857-868
(2011)
Drugs Today , vol.47
, Issue.11
, pp. 857-868
Dw, B.1
Er, K.2
Jmeno, A.3
6
84874476768
Proceedings of ASCO LBA 8500
Hauschild A et al (2012) Proceedings of ASCO LBA 8500. J Clin Oncol 30
(2012)
J Clin Oncol , pp. 30
Hauschild, A.1
7
84866882009
Trametinib for patients with advanced melanoma
23026823 10.1016/S1470-2045(12)70419-9 1:CAS:528:DC%2BC38XhsVCjsbnI
Masuda S, Izpisua Belmonte JC (2012) Trametinib for patients with advanced melanoma. Lancet Oncol 13(10):e409
(2012)
Lancet Oncol , vol.13
, Issue.10
, pp. 409
Masuda, S.1
Izpisua Belmonte, J.C.2
8
84860728453
Targeting regulatory T cells
10.1007/s11523-012-0208-y
Menetrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W (2012) Targeting regulatory T cells. Targeted Oncol 7(1):15-28
(2012)
Targeted Oncol , vol.7
, Issue.1
, pp. 15-28
Menetrier-Caux, C.1
Curiel, T.2
Faget, J.3
Manuel, M.4
Caux, C.5
Zou, W.6
9
84874488768
Overview of targeted anticancer therapies
in press
Li J, Chen F, Miranda M et al (2012) Overview of targeted anticancer therapies. Target Oncol (in press)
(2012)
Target Oncol
Li, J.1
Chen, F.2
Miranda, M.3
10
84868520609
Trastuzumab Emtansine for HER2-positive advanced breast cancer
23020162 10.1056/NEJMoa1209124 1:CAS:528:DC%2BC38Xhs1ekt73M
Verma S et al (2012) Trastuzumab Emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791
(2012)
N Engl J Med , vol.367
, pp. 1783-1791
Verma, S.1
